Would you consider using tamoxifen in ER-negative DCIS?

In the placebo-controlled NSABP-B24 trial, tamoxifen reduced the risk of ipsilateral and contralateral second events by 30% and 52%, respectively, when added to BCS and radiation. In a reanalysis of a subset of participants with estrogen receptor expression information, this benefit was most apparen...

no

In the randomized controlled trials of adjuvant tamoxifen for DCIS, only women with hormone receptor-positive tumors benefited. Also there is a strong correlation between hormone receptor status of the primary breast cancer and contralateral second breast primaries. Therefore, women with a history o...